STM Journals Peer-reviewed research from Consortium e-Learning Network

Research & Reviews: A Journal of Drug Design & Discovery

Zika Virus E-Protein In Silico Approach and Drug Repurposing

  1. C. Sameer
  2. A. P. Tanvee
  3. A. Nivedha

Abstract

The mosquito borne, one of the flavivirus family, called Zika virus is a positive, single stranded RNA. ZIKV infected humans are affected by neurological disorders, birth defects and other small pain, rash etc. To relieve from these disease, the target protein of ZIKV disease is to be determined. Here, the envelope protein is taken as a target to prevent Zika virus entry in to the cells. 3D structure of ZIKV deposited in the PDB (5ire) is used as the receptor. The FASTA sequence of 5ire is retrieved and modelled to get a good quality structure. Drugs that have potential effect on the target protein are to be studied. In previous research, many drugs were developed for flavivirus disease and used as antivirals and inhibitors. These drugs that are capable of inhibiting the viral entry and the replication process are to be studied. Amodiaquine (AQ), Chloroquine (CQ), Umifenovir, Catenospermine (CAT) and Deoxydojrimycin (DNJ) are used as the drug targets for the envelope (E) protein of various viral diseases like, dengue fever, influenza, west nile virus, Japanese encephalitis virus etc. These drugs are repurposed to study the activity against the ZIKV envelope protein, in the current study. Structure based ligand docking is used to determine the binding site of the protein. Keywords: BLAST, Modeller 9.16, Procheck, Rampage, Ligplot, Zinc pharmer, Auto dock 4.0Cite this ArticleSameer C, Tanvee AP, Nivedha A. Zika Virus E-Protein In Silico Approach and Drug Repurposing. Research & Reviews: A Journal of Drug Design & Discovery. 2017; 4(2): 8-16p.

References (21)

  1. Guardia C, De La , Lleonart Ricardo. Progress in the Identification of Dengue Virus. Entry/FusionInhibitors.BMRI.2014.13:1 http:// dx.doi.org/10.1155/2014/825039.
  2. Hamel R, Dejarnac O, Wichit , et al. Biology of Zika Virus Infection in Human Skin Cell s. J Virol. 2015. http://dx.doi.org/10.1128/JVI.00354-15.
  3. Okia N, George PV, Tukei PM , et al. Arbovirus Survey in Wild Birds in Uganda East. Afr Med J. 1971; 48(12): 725–31p.
  4. Olson JG, Ksiazek TG, Gubler DJ, et al. A Survey for Arboviral Antibodies in Sera of Humans and Animals in Lombok, Republic of Indonesia. Ann Trop Med Parasitol. 1983; 77(2): 131–7p.
  5. Musso D, Nhan T, Robin E , et al . Potential for Zika Virus Transmissi on through Blood Transfusion Dem onstrated during an Outbreak in French Polynesia, November 2013 to February 2014. Euro Surveill. 2014; 19(14).
  6. Musso D, Roche C, Robin E , et al . Potential Sexual Transmis sion of Zika Virus. Emerg Infect Dis. 2015; 21(2): 359–61p.
  7. Oster AM, Brooks JT, Stryker JE , et al . Interim Guidelines for Prevention of Sexual Transmission of Zika Virus United States, 2016. MMWR Morb Mortal Wkly Rep. 2016; 65(5): 120–1p.
  8. Atkinson B, Hearn P, Afrough B , et al . Detection of Zika Virus in Semen. Emerg Infect Dis. 2016.
  9. Robert WM, Homa n J, Michael Callahan V, et al . Zika Virus: Medical Countermeasure Development Challenges. PLoS Ntd. 2016; 10(3).
  10. Besnard M, Lastere S, Teissier A , et al . Evidence of Perinatal Transm ission of Zika Virus, French Polynesia, December 2013 and February 2014. Euro Surveill . 2014; 19(13).
  11. Hayes B. Zika Virus Outside of Africa. CRESIB. 2009; 15(9).
  12. Mohammad Mahfuz A, Shawan, Hafij M , et al. Insilco Modelling and Immunoinformatics Probing Disclose the Epitope Based Peptide Vaccine against Zika Virus Envelope Glycoprotein. IJPBR. 2014; 2(4): 44–57p.
  13. Linden Bach BD, Murray CL, Thile H -J, et al. Flaviviridae: The Viruses and Their Replication. In Fields Virology . LWW. 2013; 1: 1p.
  14. Delvecchio R, Higa M, Pezzuto Pa ula, et al. CQ Inhibits Zika Virus Infection in 1 Different Cellular Models. Bio Rxiv. 2016.
  15. Pierson C , Engle M, Yi Zhou. Catenospermine, a Potent Inhibitor of Dengue Virus Infection In Vitro and In Research & Reviews: A Journal of Drug Design & Discovery Volume 4, Issue 2 ISSN: 2349-9036 (Online) RRJoDDD (2017) 8-16 © STM Journals 2017. All Rights Reserved Page 16 Vivo. ASM. 2005; 79.
  16. Fusco DN, Chung RT. Review of Current Dengue Treatment and Therapeutics in Development. J Bio Anal Biomed. 2014; S8: 002p.
  17. Grard G, Moureau G, et al. Genomics and Evolution of Aedes -Borne Flaviviruses. J Gen Virol. 2010; 91: 89p.
  18. Sirohi D, Chen Zhenguo, Sun L, et al. The 3.8 Å Resolution Cryo -EM Structure of Zika Virus. Sciencemag. 2016; 2.
  19. Eswar N, Eramian D, Webb B, et al. Protein Structure Modelling with Modeller, University of California. Springer link. 2008; 3p.
  20. Wang Jennifer. Protein Structure Prediction by Comparative Modelling: An Analysis of Methodology. Citeseer. 2009; 1–4, 7–8p.
  21. Agnihotri S, Narula R, Joshi K , et al . In Silco Modelling of Ligand Molecu le for Non-Structural 3 (NS3) Protein Target of Flavi Viruses. BMI. 2011; 8(3). Cite this Article Sameer C, Tanvee AP, Nivedha A. Zika Virus E -Protein In Silico Approach and Drug Repurposing. Research & Reviews: A Journal of Drug Design & Discovery . 2017; 4(2): 8–16p.
Support